Hypofractionation for Soft Tissue Sarcoma

Modern trends throughout radiation oncology have favored short-course hypofractionated regimens which are frequently more cost-effective and convenient for patients. Over the past two years, multiple prospective studies have emerged supporting hypofractionation in soft tissue sarcoma. These studies include a variety of fractionation, techniques and endpoints. There is a need to both increase awareness of this new approach and synthesize the data for a general audience. In this activity, a panel of experts review the data supporting hypofractionation for STS. This includes the positive benefits patients might derive as well as limitations of our current knowledge base. This educational activity includes practical highlights, including indications for and techniques applied in published studies of hypofractionation, including patient selection, dose and margins.

Topics:

  1. Historic Background and Rationale for Hypofractionation in Sarcoma
    Andrew J. Bishop, MD
  2. "Ultra" Hypo-Fractionated Preoperative Radiation Therapy for Soft Tissue Sarcoma
    Anusha Kalbasi, MD
  3. Moderate vs. Ultra Hypo-Fractionated Radiation in Soft Tissue Sarcomas
    Manpreet Bedi, MD, MS
  4. Case Presentations and Q&A
    Full Panel

This activity is available from December 3, 2024, through 11:59 p.m. Eastern time on December 2, 2026. 

This activity was originally recorded at the 2024 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, surgeons, physicists, radiation therapists, radiation dosimetrists and residents.  

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select patients with sarcoma who may benefit from hypofractionated regimens. 
  • Use safe and effective techniques (fractionation, target design, etc.) supported by the prospective data on hypofractionated radiotherapy for sarcoma. 
  • Effectively convey the pros and cons of hypofractionated radiation to patients and other members of the multidisciplinary sarcoma team. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
12/03/2024
Course expires: 
12/02/2026
Cost:
$149.00
Rating: 
0
  • Daniel J. Indelicato, MD, is employed by University of Florida College of Medicine. Dr. Indelicato receives honoraria from the NCI CIRB. Dr. Indelicato serves as Education Chair of the Pediatric Radiation Oncology Society. 
  • Manpreet Bedi, MD, MS, is employed by the Medical College of Wisconsin. Dr. Bedi receives honoraria from Varian and Accuray. 
  • Anusha Kalbasi, MD, is employed by Stanford University School of Medicine. Dr. Kalbasi serves on the advisory board and owns stock in Certis Oncology. Dr. Kalbasi receives compensation from T Cure Therapeutics and grant/research funding from Highlight Therapeutics.
  • Andrew J. Bishop, MD, is employed by The University of Texas MD Anderson Cancer Center. 

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until December 2, 2026, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.